Trough peak ratios: Are there differences between antihypertensive drugs?

Peak and Trough.

Are There Differences between Launched Drugs, Clinical Candidates, and Commercially Available Compounds?

To clarify the differences between commercially available compounds, clinical candidates, and launched drugs with regard to distribution of physicochemical properties and to characterize the correlation between physicochemical properties, we conducted analyses on physicochemical descriptors of commercially available compounds, clinical candidates, and launched drugs. Initial analysis of the mar...

Reproducibility and Clinical Value of the Trough-to-Peak Ratio of the Antihypertensive Effect

The objectives of our study were to assess the reproducibility of the trough-to-peak ratio (T/P) and to see whether a high T/P is accompanied by more organ protection or vice versa. The study included 175 (mean6SD age, 5169 years) subjects with mild-moderate essential hypertension who had echocardiographic evidence of left ventricular (LV) hypertrophy taken from the SAMPLE study (Study on Ambul...

Why are there deadly drugs?

Some drugs eventually have to be removed from the market because of a negative benefit-to-harm ratio, including an excess of mortality. Drug safety is the result of multiple factors, commencing with how clinical trials are designed, the information generated by and/or hidden through these trials, trial analysis by drug regulatory authorities (DRAs) and the amount of information that DRAs choose...

Antihypertensive drug use and adherence after stroke: are there sex differences?

BACKGROUND AND PURPOSE The majority of stroke fatalities occur in elderly women. We compared prescribing and adherence to antihypertensive therapies shown to reduce fatal and nonfatal stroke recurrence among elderly women and men with acute stroke. METHODS Using the Registry of the Canadian Stroke Network, we identified all patients >or=66 years of age discharged home from 11 tertiary care ce...